

DAFTAR PUSTAKA

- American Diabetes Association, 2014a. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, **37**: S81–S90.
- American Diabetes Association, 2014b. Standards of Medical Care in Diabetes--2014. *Diabetes Care*, **37**: S14–S80.
- American Pharmacist Association, 2012. *Drug Information Handbook*, 20th ed. Lexi-comp, Ohio, USA.
- Avery, P., Mousa, S.S., dan Mousa, S.A., 2009. Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. *Pharmacogenomics and personalized medicine*, **2**: 79–91.
- Bakris, G.L. dan Molitch, M.E., 2016. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? *Diabetes Care*, **39**: 1287–1291.
- Bardin, C., Nobecourt, E., Larger, E., Chast, F., Treluyer, J.-M., dan Urien, S., 2012. Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. *European Journal of Clinical Pharmacology*, **68**: 961–968.
- Becker, M., Visser, L.E., van Schaik, R.H.N., Hofman, A., Uitterlinden, A.G., dan Stricker, B.H.C., 2009a. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. *The pharmacogenomics journal*, **9**: 242–247.
- Becker, M.L., Visser, L.E., Schaik, R.H.N. van, Hofman, A., Uitterlinden, A.G., dan Stricker, B.H.C., 2009b. Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study. *Diabetes*, **58**: 745–749.
- Becker, M.L., Visser, L.E., van Schaik, R.H.N., Hofman, A., Uitterlinden, A.G., dan Stricker, B.H.C., 2010. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. *Pharmacogenetics and genomics*, **20**: 38–44.
- Bodmer, M., Meier, C., Krähenbühl, S., Jick, S.S., dan Meier, C.R., 2008. Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. *Diabetes Care*, **31**: 2086–2091.
- Boucaud-Maitre, D., Ropers, J., Porokhov, B., Altman, J.-J., Bouhanick, B., Doucet, J., dkk., 2016. Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. *Diabetic Medicine: A Journal of the British Diabetic Association*, **33**: 1536–1543.
- Bozkurt, O., de Boer, A., Grobbee, D.E., Heerdink, E.R., Burger, H., dan Klungel, O.H., 2007. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. *Molecular diagnosis & therapy*, **11**: 291–302.
- Briet, C., Saraval-Gross, M., Kajbaf, F., Fournier, A., Hary, L., dan Lalau, J.-D., 2012. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. *Clinical Kidney Journal*, **5**: 65–67.

- Chen, L., Takizawa, M., Chen, E., Schlessinger, A., Segenthar, J., Choi, J.H., dkk., 2010. Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function. *The Journal of Pharmacology and Experimental Therapeutics*, **335**: 42–50.
- Chen, M.L., Lee, S.C., Ng, M.J., Schuirmann, D.J., Lesko, L.J., dan Williams, R.L., 2000. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. *Clinical Pharmacology and Therapeutics*, **68**: 510–521.
- Chen, Y., Teranishi, K., Li, S., Yee, S.W., Hesselson, S., Stryke, D., dkk., 2009. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. *The Pharmacogenomics Journal*, **9**: 127–136.
- Choi, M.-K. dan Song, I.-S., 2008. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. *Drug Metabolism and Pharmacokinetics*, **23**: 243–253.
- Christensen, M.M., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., dkk., 2015b. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1: Corrigendum. *Pharmacogenetics and Genomics*, 48–50.
- Christensen, M.M.H., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., dkk., 2011. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. *Pharmacogenetics and Genomics*, **21**: 837–850.
- Christensen, M.M.H., Højlund, K., Hother-Nielsen, O., Stage, T.B., Damkier, P., Beck-Nielsen, H., dkk., 2015a. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. *European Journal of Clinical Pharmacology*, **71**: 691–697.
- Christensen, M.M.H., Pedersen, R.S., Stage, T.B., Brasch-Andersen, C., Nielsen, F., Damkier, P., dkk., 2013. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. *Pharmacogenetics and Genomics*, **23**: 526–534.
- Cockcroft, D.W. dan Gault, M.H., 1976. Prediction of creatinine clearance from serum creatinine. *Nephron*, **16**: 31–41.
- Cook, M.N., Girman, C.J., Stein, P.P., dan Alexander, C.M., 2007. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. *Diabetic Medicine: A Journal of the British Diabetic Association*, **24**: 350–358.
- Dahlan, M.S., 2013. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*, 3rd ed. Salemba Medika Jakarta.
- Danese, E., Montagnana, M., Nouvenne, A., dan Lippi, G., 2015. Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes. *Journal of Diabetes Science and Technology*, **9**: 169–176.
- Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R., Palmer, C.N.A., dan Pearson, E.R., 2015. Association of Organic Cation Transporter 1 With Intolerance

- to Metformin in Type 2 Diabetes: A GoDARTS Study. *Diabetes*, **64**: 1786–1793.
- Duong, J.K., Kumar, S.S., Kirkpatrick, C.M., Greenup, L.C., Arora, M., Lee, T.C., dkk., 2013. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. *Clinical Pharmacokinetics*, **52**: 373–384.
- FDA, 1995. Metformin hydrochloride tablets.
- FDA, 1994. Reviewer Guidance Validation of Chromatographic Methods. Cent Drug Eval Res CDER.
- Foretz, M. dan Viollet, B., 2011. Regulation of hepatic metabolism by AMPK. *Journal of Hepatology*, **54**: 827–829.
- Freire, A.C., Basit, A.W., Choudhary, R., Piong, C.W., dan Merchant, H.A., 2011. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. *International Journal of Pharmaceutics*, **415**: 15–28.
- Frid, A., Sterner, G.N., Londahl, M., Wiklander, C., Cato, A., Vinge, E., dkk., 2010. Novel assay of Metformin Levels in Patients with Type 2 Diabetes and Varying Levels of Renal Function. *Diabetes Care*, **33**: .
- Furusyo, N., Koga, T., Ai, M., Otokozawa, S., Kohzuma, T., Ikezaki, H., dkk., 2011. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: Results from the Kyushu and Okinawa Population Study (KOPS). *Diabetologia*, **54**: 3028–3036.
- Garber, A., Marre, M., Blonde, L., Allavoine, T., Howlett, H., Lehert, P., dkk., 2003. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. *Diabetes, Obesity & Metabolism*, **5**: 171–179.
- Garber, A.J., Duncan, T.G., Goodman, A.M., Mills, D.J., dan Rohlf, J.L., 1997. Efficacy of Metformin in Type II Diabetes. *The American Journal of Medicine*, **103**: 491–497.
- Ghiculescu, R., 2008. Abnormal laboratory results. Therapeutic drug monitoring: which drugs, why, when and how to do it. *Aust Prescr*, **31**: 42.
- Ghobadi, C., Johnson, T.N., Aarabi, M., Almond, L.M., Allabi, A.C., Rowland-Yeo, K., dkk., 2011. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. *Clinical Pharmacokinetics*, **50**: 809–822.
- Giannoudis, A., Wang, L., Jorgensen, A.L., Xinarianos, G., Davies, A., Pushpakom, S., dkk., 2013. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. *Blood*, **121**: 628–637.
- Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B., dan Klein, T.E., 2012. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenetics and Genomics*, **22**: 820–827.
- Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J.K., dkk., 2011. Clinical Pharmacokinetics of Metformin: *Clinical Pharmacokinetics*, **50**: 81–98.

- Grimm, D., Lieb, J., Weyer, V., Vollmar, J., Darstein, F., Lautem, A., dkk., 2016. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. *BMC cancer*, **16**: 94.
- Grinfeld, J., Gerrard, G., Alikian, M., Alonso-Dominguez, J., Ale, S., Valgañon, M., dkk., 2013. A common novel splice variant of *SLC22A1* (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. *British Journal of Haematology*, **163**: 631–639.
- Group, D.P.P.R., 2002. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *New England Journal of Medicine*, **346**: 393–403.
- Hakim, L., 2016. *Optimasi Dosis : Aplikasi Farmakokinetik Dalam Penemuan Obat Dan Pengobatan*, Pertama. ed, Seri Penemuan Obat dan Farmasi Klinik. Bursa Ilmu, Yogyakarta.
- Han, T. (Kevin), Everett, R.S., Proctor, W.R., Ng, C.M., Costales, C.L., Brouwer, K.L.R., dkk., 2013. Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes. *Molecular Pharmacology*, **84**: 182–189.
- Han, T. (Kevin), Proctor, W.R., Costales, C.L., Cai, H., Everett, R.S., dan Thakker, D.R., 2015. Four Cation-Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell Monolayers. *The Journal of Pharmacology and Experimental Therapeutics*, **352**: 519–528.
- He, R., Zhang, D., Lu, W., Zheng, T., Wan, L., Liu, F., dkk., 2015. *SLC47A1* gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. *Diabetes Research and Clinical Practice*, **109**: 57–63.
- Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.-L., dan Karlsson, J., 2007. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines. *Drug Metabolism and Disposition*, **35**: 1333–1340.
- Hoerger, T.J., Segel, J.E., Gregg, E.W., dan Saaddine, J.B., 2008. Is Glycemic Control Improving in U.S. Adults? *Diabetes Care*, **31**: 81–86.
- Holstein, A., Seeringer, A., dan Kovacs, P., 2011. Therapy with oral antidiabetic drugs: applied pharmacogenetics. *The British Journal of Diabetes & Vascular Disease*, **11**: 10–16.
- Hur, K.Y. dan Lee, M.-S., 2015. New mechanisms of metformin action: Focusing on mitochondria and the gut. *Journal of Diabetes Investigation*, **6**: 600–609.
- Indonesian association of Endocrinologists/Perkeni, 2015. Consensus on Type-2 Diabetes Mellitus Control and Prevention in Indonesia.
- International Diabetes Federation, 2015. Indonesia VS World Prevalence of Diabetes.
- Ji, L., Li, H., Guo, X., Li, Y., Hu, R., dan Zhu, Z., 2013. Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial. *PLoS ONE*, **8**:2
- Jones, G.C., Macklin, J.P., dan Alexander, W.D., 2003. Contraindications to the use of metformin. *BMJ : British Medical Journal*, **326**: 4–5.

- Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., dkk., 2006. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. *New England Journal of Medicine*, **355**: 2427–2443.
- Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A.-S., Andréjak, M., dan Lalau, J.-D., 2016. Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. *Diabetic Medicine: A Journal of the British Diabetic Association*, **33**: 105–110.
- Kajbaf, F. dan Lalau, J.-D., 2013. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. *BMC Pharmacology & Toxicology*, **14**: 22.
- Karim, A., Slater, M., Bradford, D., Schwartz, L., dan Laurent, A., 2007. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. *Journal of Clinical Pharmacology*, **47**: 48–55.
- Kavvoura, F.K., Pappa, M., Evangelou, E., dan Ntzani, E.E., 2013. The Genetic Architecture of Type 2 Diabetes Pharmacotherapy: The Emerging Genomic Evidence. *Current pharmaceutical design*, .
- Kim, K.J. dan Lee, B.-W., 2012. The Roles of Glycated Albumin as Intermediate Glycation Index and Pathogenic Protein. *Diabetes & Metabolism Journal*, **36**: 98–107.
- Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., dan Brockmüller, J., 2005. Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance. *Clinical Pharmacokinetics*, **44**: 1209–1225.
- Klen, J., Goričar, K., Janež, A., dan Dolžan, V., 2014. The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment. *BioMed Research International*, .
- Klonoff, D.C., 2008. Personalized Medicine for Diabetes. *Journal of diabetes science and technology (Online)*, **2**: 335–341.
- Koepsell, H., Lips, K., dan Volk, C., 2007. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications. *Pharmaceutical Research*, **24**: 1227–1251.
- Koga, M. dan Kasayama, S., 2010. Clinical impact of glycated albumin as another glycemic control marker. *Endocrine Journal*, **57**: 751–762.
- Kumpatla, S., Tilak, P., dan Viswanathan, V., 2011. Efficacy of glycated albumin (GA) in comparison with glycated Haemoglobin (HbA1c) in type 2 Diabetic Subject in India. *JK Science*, **13**: 6–10.
- Kusuhara, H., Ito, S., Kumagai, Y., Jiang, M., Shiroshta, T., Moriyama, Y., dkk., 2011. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. *Clinical Pharmacology and Therapeutics*, **89**: 837–844.
- Lalau, J.-D., 2010. Lactic Acidosis Induced by Metformin: Incidence, Management and Prevention. *Drug Saf*, **33**: 727–740.

- Lalau, J.-D., Kajbaf, F., Lalau, J.-D., dan Kajbaf, F., 2014. Interpreting the Consequences of Metformin Accumulation in an Emergency Context: Impact of the Time Frame on the Blood Metformin Levels, Interpreting the Consequences of Metformin Accumulation in an Emergency Context: Impact of the Time Frame on the Blood Metformin Levels. *International Journal of Endocrinology, International Journal of Endocrinology*, **2014**: e717198.
- Lalau, J.-D. dan Lacroix, C., 2003. Measurement of metformin concentration in erythrocytes: clinical implications. *Diabetes, Obesity and Metabolism*, **5**: 93–98.
- Lalau, J.D. dan Race, J.M., 1999. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. *Drug Safety*, **20**: 377–384.
- Lalau, J.D., Vermersch, A., Hary, L., Andrejak, M., Isnard, F., dan Quichaud, J., 1990. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). *International Journal of Clinical Pharmacology, Therapy, and Toxicology*, **28**: 329–332.
- Leabman, M.K. dan Giacomini, K.M., 2003. Estimating the contribution of genes and environment to variation in renal drug clearance. *Pharmacogenetics*, **13**: 581–584.
- Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y. (Lucy), Castro, A.F., Feldman, H.I., dkk., 2009. A New Equation to Estimate Glomerular Filtration Rate. *Annals of internal medicine*, **150**: 604–612.
- Lickteig, A.J., Cheng, X., Augustine, L.M., Klaassen, C.D., dan Cherrington, N.J., 2008. Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. *Life sciences*, **83**: 59–64.
- Lipska, K.J., Bailey, C.J., dan Inzucchi, S.E., 2011. Use Of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. *Diabetes Care*, **34**: .
- Mahrooz, A., Parsanasab, H., Hashemi-Soteh, M.B., Kashi, Z., Bahar, A., Alizadeh, A., dkk., 2015. The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study. *Clinical and Experimental Medicine*, **15**: 159–165.
- Mangoni, A.A. dan Jackson, S.H.D., 2004. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *British Journal of Clinical Pharmacology*, **57**: 6–14.
- Marathe, P.H., Arnold, M.E., Meeker, J., Greene, D.S., dan Barbhaiya, R.H., 2000. Pharmacokinetics and Bioavailability of a Metformin/Glyburide Tablet Administered Alone and with Food. *The Journal of Clinical Pharmacology*, **40**: 1494–1502.
- McCreight, L.J., Bailey, C.J., dan Pearson, E.R., 2016. Metformin and the gastrointestinal tract. *Diabetologia*, **59**: 426–435.
- Meibohm, B., Beierle, I., dan Derendorf, H., 2002. How Important Are Gender Differences in Pharmacokinetics? *Clinical Pharmacokinetics*, **41**: 329–342.
- Michels, W.M., Grootendorst, D.C., Verduijn, M., Elliott, E.G., Dekker, F.W., dan Krediet, R.T., 2010. Performance of the Cockcroft-Gault, MDRD, and New

- CKD-EPI Formulas in Relation to GFR, Age, and Body Size. *Clinical Journal of the American Society of Nephrology : CJASN*, **5**: 1003–1009.
- Ministry of Health of the Republic of Indonesia/Kemenkes RI, 2013. Riset Kesehatan Dasar 2013.
- Ministry of Health of the Republic of Indonesia/Kemenkes RI, 2014. PMK RI: Standar pelayanan kefarmasian di Rumah Sakit.
- Ministry of Health of the Republic of Indonesia/Kemenkes RI, 2016. National Formulary.
- Müller, J., Lips, K.S., Metzner, L., Neubert, R.H.H., Koepsell, H., dan Brandsch, M., 2005. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). *Biochemical Pharmacology*, **70**: 1851–1860.
- Nathan, D.M., McGee, P., Steffes, M.W., dan Lachin, J.M., 2014. Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study. *Diabetes*, **63**: 282–290.
- National Institute of Diabetes and Digestive and Kidney Diseases, 2009. The A1C Test and Diabetes **32**: 1327–1334.
- Nies, A.T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., dkk., 2009. Expression of organic cation transporters OCT1 (*SLC22A1*) and OCT3 (*SLC22A3*) is affected by genetic factors and cholestasis in human liver. *Hepatology*, **50**: 1227–1240.
- Ningrum, V.D.A., Ikawati, Z., Sadewa, A.H., dan Ikhsan, M.R., 2017b. Kontrol Glikemik dan Prevalensi Gagal Ginjal Kronik pada Pasien DM tipe 2 di Puskesmas Wilayah Propinsi DIY Tahun 2015. *Indonesian Journal of Clinical Pharmacy (in press)*, .
- Ningrum, V.D.A., Ikawati, Z., Sadewa, A.H., Ikhsan, M.R., dan Saepudin, S., 2017a. Steady-state Pharmacokinetics of Metformin in Obese Patients with Type 2 Diabetes Mellitus: a Preliminary Study. *Asian Journal of Pharmaceutical and Clinical Research*, **10**: 294–298.
- Ningrum, V.D.A., Ikawati, Z., Sadewa, A.H., Ikhsan, M.R., dan Yunilistianingsih, 2017c. Faktor Pasien yang Mempengaruhi Respon Glikemik Penggunaan Monoterapi Metformin pada Diabetes Melitus Tipe 2. *Jurnal Manajemen dan Pelayanan Farmasi (in press)*, .
- Ono, C., Kikkawa, H., Suzuki, A., Suzuki, M., Yamamoto, Y., Ichikawa, K., dkk., 2013. Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. *Pharmacogenomics*, **14**: 1745–1764.
- Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H., dan Moriyama, Y., 2005. A human transporter protein that mediates the final excretion step for toxic organic cations. *Proceedings of the National Academy of Sciences of the United States of America*, **102**: 17923–17928.
- Reitman, M.L. dan Schadt, E.E., 2007. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. *Journal of Clinical Investigation*, **117**: 1226–1229.

- Rena, G., Pearson, E.R., dan Sakamoto, K., 2013. Molecular mechanism of action of metformin: old or new insights? *Diabetologia*, **56**: 1898–1906.
- Ritschel, W. dan Kearns, G., 2004. *Handbook of Basic Pharmacokinetics Including Clinical Applications*, sixth. ed. American Pharmacist Association, Washington DC.
- Robert, F., Fendri, S., Hary, L., Lacroix, C., Andréjak, M., dan Lalau, J.D., 2003. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. *Diabetes & Metabolism*, **29**: 279–283.
- Roden, D.M., Altman, R.B., Benowitz, N.L., Flockhart, D.A., Giacomini, K.M., Johnson, J.A., dkk., 2006. Pharmacogenomics: Challenges and Opportunities. *Annals of Internal Medicine*, **145**: 749–757.
- Rojas, L.B.A. dan Gomes, M.B., 2013. Metformin: an old but still the best treatment for type 2 diabetes. *Diabetology & Metabolic Syndrome*, **5**: 6.
- Roohk, H.V. dan Zaidi, A.R., 2008. A Review of Glycated Albumin as an Intermediate Glycation Index for Controlling Diabetes. *Journal of diabetes science and technology (Online)*, **2**: 1114–1121.
- Roth, M., Obaidat, A., dan Hagenbuch, B., 2012. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. *British Journal of Pharmacology*, **165**: 1260–1287.
- Saffar, F., Aiache, J.M., dan Andre, P., 1995. Influence of food on the disposition of the antidiabetic drug metformin in diabetic patients at steady-state. *Methods and Findings in Experimental and Clinical Pharmacology*, **17**: 483–487.
- Sambol, N.C., Brookes, L.G., Chiang, J., Goodman, A.M., Lin, E.T., Liu, C.Y., dkk., 1996. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. *British Journal of Clinical Pharmacology*, **42**: 510–512.
- Sambol, N.C., Chiang, J., Lin, E.T., Goodman, A.M., Liu, C.Y., Benet, L.Z., dkk., 1995. Kidney Function and Age Are Both Predictors of Pharmacokinetics of Metformin. *The Journal of Clinical Pharmacology*, **35**: 1094–1102.
- Sambol, N.C., Chiang, J., O’Conner, M., Liu, C.Y., Lin, E.T., Goodman, A.M., dkk., 1996. Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Subjects and Patients with Noninsulin-Dependent Diabetes Mellitus. *The Journal of Clinical Pharmacology*, **36**: 1012–1021.
- Scarpello, J.H., 2001. Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. *The British Journal of Diabetes & Vascular Disease*, **1**: 28–36.
- Schlatter, E., Klassen, P., Massmann, V., Holle, S.K., Guckel, D., Edemir, B., dkk., 2014. Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules. *Pflügers Archiv - European Journal of Physiology*, **466**: 1581–1589.
- Schwartz, S., Fonseca, V., Berner, B., Cramer, M., Chiang, Y.-K., dan Lewin, A., 2006. Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes. *Diabetes Care*, **29**: 759–764.

- Shargel, L., Wu-Pong, S., dan Yu, A.B.C., 2005. *Applied Biopharmaceutics and Pharmacokinetics*. Mc Graw Hill, New York: Appleton & Lange Reviews.
- Shikata, E., Yamamoto, R., Takane, H., Shigemasa, C., Ikeda, T., Otsubo, K., dkk., 2006. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. *Journal of Human Genetics*, **52**: 117–122.
- Shu, Y., Brown, C., Castro, R.A., Shi, R.J., Lin, E.T., Owen, R.P., dkk., 2008. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. *Clinical Pharmacology and Therapeutics*, **83**: 273–280.
- Soldin, O. dan Mattison, D., 2009. Sex Differences in Pharmacokinetics and Pharmacodynamics. *Clinical pharmacokinetics*, **48**: 143–157.
- Stades, A.M.E., Heikens, J.T., Erkelens, D.W., Holleman, F., dan Hoekstra, J.B.L., 2004. Metformin and lactic acidosis: cause or coincidence? A review of case reports. *Journal of Internal Medicine*, **255**: 179–187.
- Stocker, S.L., Morrissey, K.M., Yee, S.W., Castro, R.A., Xu, L., Dahlin, A., dkk., 2013. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. *Clinical pharmacology and therapeutics*, **93**: 186–194.
- Sumitani, S., Morita, S., Deguchi, R., Hirai, K., Mukai, K., Utsu, Y., dkk., 2015. Metformin decreases glycated albumin to glycated haemoglobin ratio in patients with newly diagnosed type 2 diabetes. *Annals of Clinical Biochemistry*, **52**: 76–81.
- Tahrani, A.A., Varughese, G.I., Scarpello, J.H., dan Hanna, F.W.F., 2007. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? *BMJ: British Medical Journal*, **335**: 508–512.
- Takahashi, H. dan Echizen, H., 2003. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. *The Pharmacogenomics Journal*, **3**: 202–214.
- Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O., dan Inui, K.-I., 2007. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. *Biochemical Pharmacology*, **74**: 359–371.
- Tarasova, L., Kalnina, I., Geldnere, K., Bumbure, A., Ritenberga, R., Nikitina-Zake, L., dkk., 2012. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. *Pharmacogenetics and Genomics*, **22**: 659–666.
- Tkáč, I., Klimčáková, L., Javorský, M., Fabianová, M., Schroner, Z., Hermanová, H., dkk., 2013. Pharmacogenomic association between a variant in *SLC47A1* gene and therapeutic response to metformin in type 2 diabetes. *Diabetes, Obesity & Metabolism*, **15**: 189–191.
- Toyama, K., Yonezawa, A., Masuda, S., Osawa, R., Hosokawa, M., Fujimoto, S., dkk., 2012. Loss of multidrug and toxin extrusion 1 (MATE1) is associated

- with metformin-induced lactic acidosis. *British Journal of Pharmacology*, **166**: 1183–1191.
- Toyama, K., Yonezawa, A., Tsuda, M., Masuda, S., Yano, I., Terada, T., dkk., 2010. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. *Pharmacogenetics and genomics*, **20**: 135–138.
- Tucker, G.T., Casey, C., Phillips, P.J., Connor, H., Ward, J.D., dan Woods, H.F., 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *British Journal of Clinical Pharmacology*, **12**: 235–246.
- Tzvetkov, M.V., Vormfelde, S.V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., dkk., 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. *Clinical pharmacology and therapeutics*, **86**: 299–306.
- Umamaheswaran, G., Praveen, R.G., Arunkumar, A.S., Das, A.K., Shewade, D.G., dan Adithan, C., 2011. Genetic analysis of OCT1 gene polymorphisms in an Indian population. *Indian Journal of Human Genetics*, **17**: 164–168.
- Umamaheswaran, G., Praveen, R.G., Damodaran, S.E., Das, A.K., dan Adithan, C., 2015. Influence of *SLC22A1* rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. *Clinical and Experimental Medicine*, **15**: 511–517.
- Urakami, Y., Okuda, M., Saito, H., dan Inui, K., 2000. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. *FEBS letters*, **473**: 173–176.
- van Leeuwen, N., Nijpels, G., Becker, M.L., Deshmukh, H., Zhou, K., Stricker, B.H.C., dkk., 2012. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. *Diabetologia*, **55**: 1971–1977.
- Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M., dan Andreelli, F., 2012. Cellular and molecular mechanisms of metformin: an overview. *Clinical Science (London, England : 1979)*, **122**: 253–270.
- Wang, D.-S., Kusuvara, H., Kato, Y., Jonker, J.W., Schinkel, A.H., dan Sugiyama, Y., 2003. Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin. *Molecular Pharmacology*, **63**: 844–848.
- White, J.R., 2014. A Brief History of the Development of Diabetes Medications. *Diabetes Spectrum*, **27**: 82–86.
- Wibowo, A., Nailatulizzah, dan Ningrum, V.D.A., 2015. Bioanalytical Stability Test of Metformin Hydrochloride In Human Plasma Using Reversed-Phase HPLC-UV. *International Conference in Mathematics and Sciences Education*, .
- Wibowo, A., Ningrum, V.D.A., Fuaida, I., Ikawati, Z., Sadewa, A.H., dan Ikhsan, M.R., 2016. Validation of a HPLC-UV Method for The Determination of Metformin Hydrochloride in Spiked-Human Plasma for Application of Therapeutic Drug Monitoring. *Unpublished Data*, .
- Wright, L.A.-C. dan Hirsch, I.B., 2012. The Challenge of the Use of Glycemic Biomarkers in Diabetes: Reflecting on Hemoglobin A1C, 1,5-

- Anhydroglucitol, and the Glycated Proteins Fructosamine and Glycated Albumin. *Diabetes Spectrum*, **25**: 141–148.
- Wu, W.-C., Ma, W.-Y., Wei, J.-N., Yu, T.-Y., Lin, M.-S., Shih, S.-R., dkk., 2016. Serum Glycated Albumin to Guide the Diagnosis of Diabetes Mellitus. *PLOS ONE*, **11**: e0146780.
- Xiao, D., Guo, Y., Li, X., Yin, J.-Y., Zheng, W., Qiu, X.-W., dkk., 2016a. The Impacts of *SLC22A1* rs594709 and *SLC47A1* rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. *International Journal of Endocrinology*, **2016**: e4350712.
- Yang, C., Li, H., Wang, Z., Zhang, W., Zhou, K., Meng, J., dkk., 2012a. Glycated albumin is a potential diagnostic tool for diabetes mellitus. *Clinical Medicine, Journal of the Royal College of Physicians of London*, **12**: 568–571.
- Yoon, H., Cho, H.-Y., Yoo, H.-D., Kim, S.-M., dan Lee, Y.-B., 2013a. Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects. *The AAPS Journal*, **15**: 571–580.
- Yoon, H., Cho, H.-Y., Yoo, H.-D., Kim, S.-M., dan Lee, Y.-B., 2013b. Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects. *The AAPS Journal*, **15**: 571–580.
- Yoshiuchi, K., Matsuhisa, M., Katakami, N., Nakatani, Y., Sakamoto, K., Matsuoka, T., dkk., 2008. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. *Endocrine journal*, **55**: 503–507.
- Zamek-Gliszczynski, M.J., Bao, J.Q., Day, J.S., dan Higgins, J.W., 2013. Metformin Sinusoidal Efflux from the Liver Is Consistent with Negligible Biliary Excretion and Absence of Enterohepatic Cycling. *Drug Metabolism and Disposition*, **41**: 1967–1971.
- Zhou, K., Donnelly, L.A., Kimber, C.H., Donnan, P.T., Doney, A.S.F., Leese, G., dkk., 2009. Reduced-Function *SLC22A1* Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. *Diabetes*, **58**: 1434–1439.
- Zhou, M., Xia, L., dan Wang, J., 2007. Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine. *Drug metabolism and disposition: the biological fate of chemicals*, **35**: 1956–1962.
- Zhou, Y., Ye, W., Wang, Y., Jiang, Z., Meng, X., Xiao, Q., dkk., 2015. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. *International Journal of Clinical and Experimental Pathology*, **8**: 9533–9542.
- Zolk, O., 2012. Disposition of metformin: variability due to polymorphisms of organic cation transporters. *Annals of medicine*, **44**: 119–129.